Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.74 |
| ▸ | DRD2 | P14416 | 4/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8124961 | 1.00 | SIGMAR1 (0.74) | SIGMAR1DRD2L3MBTL1DRD4DRD3 | |
| SCHEMBL8125940 | 1.00 | SIGMAR1 (0.74) | SIGMAR1DRD2L3MBTL1DRD4DRD3 | |
| SCHEMBL8126293 | 0.96 | SIGMAR1 (0.80) | SIGMAR1DRD2DRD3 | |
| SCHEMBL8118341 | 0.94 | SIGMAR1 (0.65) | SIGMAR1DRD2DRD3 | |
| SCHEMBL8119845 | 0.93 | SIGMAR1 (0.64) | SIGMAR1DRD2DRD3 | |
| SCHEMBL8127075 | 0.89 | SIGMAR1 (0.75) | SIGMAR1DRD2L3MBTL1DRD3 | |
| SCHEMBL8120009 | 0.89 | SIGMAR1 (0.75) | SIGMAR1DRD2L3MBTL1DRD4DRD3 | |
| SCHEMBL8126235 | 0.89 | SIGMAR1 (0.75) | SIGMAR1DRD2L3MBTL1DRD4DRD3 | |
| SCHEMBL8120491 | 0.89 | SIGMAR1 (0.74) | SIGMAR1DRD2L3MBTL1DRD4DRD3 | |
| SCHEMBL8120171 | 0.89 | SIGMAR1 (0.93) | SIGMAR1DRD2L3MBTL1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190751-A1 | COMPOUNDS FOR TREATMENTS OF INFLAMMATION | ANA-MAR AB (SE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190751-A1 | COMPOUNDS FOR TREATMENTS OF INFLAMMATION | ANA-MAR AB (SE) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190751-A1 | COMPOUNDS FOR TREATMENTS OF INFLAMMATION | IL6, IL1B, TNF | SIGMAR1 1646/4885DRD2 590/4885L3MBTL1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.